...million, after it said on Tuesday Imperial College London will evaluate the efficacy of Tavalisse fostamatinib...
...Institute of MIT and Harvard researchers screened to identify FDA-approved compounds that reduce MUC1 abundance, Tavalisse...
...Mucin 1 SYK - Spleen tyrosine kinase Jeff Cranmer, Executive Editor Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...

...fostamatinib from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib...
...Inc. (NASDAQ:RIGL) for primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Novartis...

...spleen tyrosine kinase (SYK) inhibitor Tavalisse fostamatinib in adults with ITP ( No. 736 ). Tavalisse...

...Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future...
...front and is eligible for $147 million in development and commercial milestones. Rigel will supply Tavalisse...
...Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Business: Autoimmune Shannon Lehnbeuter Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Kissei...

...to a resubmitted BLA for Andexxa andexanet alfa Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) FDA approves Tavalisse fostamatinib...

...were off $0.22 to $3.84 on April 20. On April 17, FDA approved Rigel's Tavalisse fostamatinib...
...approved product (see BioCentury, April 20) . Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Paul Bonanos fostamatinib Tavalisse Rigel...

...FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic...
...be approved by any regulatory agency since its founding in 1996. Rigel expects to launch Tavalisse...
...Francisco, Calif. Business: Autoimmune Product: Tavalisse fostamatinib (formerly R788, tamatinib fosdium) Allison Johnson Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...

...Its shares were off $0.22 to $3.84 on Friday. On Tuesday, FDA approved Rigel's Tavalisse fostamatinib...

...FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic...
...be approved by any regulatory agency since its founding in 1996. Rigel expects to launch Tavalisse...
...was up a further $0.32 to $4.55 in after-hours trading. Allison Johnson Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...